ACAD
Price
$24.81
Change
+$0.42 (+1.72%)
Updated
Nov 26 closing price
Capitalization
4.2B
95 days until earnings call
Intraday BUY SELL Signals
MIRM
Price
$73.13
Change
+$1.37 (+1.91%)
Updated
Nov 26 closing price
Capitalization
3.76B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACAD vs MIRM

Header iconACAD vs MIRM Comparison
Open Charts ACAD vs MIRMBanner chart's image
ACADIA Pharmaceuticals
Price$24.81
Change+$0.42 (+1.72%)
Volume$1.88M
Capitalization4.2B
Mirum Pharmaceuticals
Price$73.13
Change+$1.37 (+1.91%)
Volume$402.92K
Capitalization3.76B
ACAD vs MIRM Comparison Chart in %
ACAD
Daily Signal:
Gain/Loss:
MIRM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ACAD vs. MIRM commentary
Nov 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and MIRM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 27, 2025
Stock price -- (ACAD: $24.83 vs. MIRM: $73.21)
Brand notoriety: ACAD and MIRM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 94% vs. MIRM: 62%
Market capitalization -- ACAD: $4.2B vs. MIRM: $3.76B
ACAD [@Biotechnology] is valued at $4.2B. MIRM’s [@Biotechnology] market capitalization is $3.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $109.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileMIRM’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • MIRM’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACAD and MIRM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while MIRM’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 3 bearish.
  • MIRM’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MIRM is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +7.49% price change this week, while MIRM (@Biotechnology) price change was +3.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -1.24%, and the average quarterly price growth was +71.95%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 02, 2026.

MIRM is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($4.2B) has a higher market cap than MIRM($3.76B). MIRM YTD gains are higher at: 77.050 vs. ACAD (35.313). ACAD has higher annual earnings (EBITDA): 104M vs. MIRM (-18.79M). ACAD has more cash in the bank: 762M vs. MIRM (305M). ACAD has less debt than MIRM: ACAD (56.3M) vs MIRM (319M). ACAD has higher revenues than MIRM: ACAD (1.02B) vs MIRM (429M).
ACADMIRMACAD / MIRM
Capitalization4.2B3.76B112%
EBITDA104M-18.79M-553%
Gain YTD35.31377.05046%
P/E Ratio16.02N/A-
Revenue1.02B429M238%
Total Cash762M305M250%
Total Debt56.3M319M18%
FUNDAMENTALS RATINGS
ACAD vs MIRM: Fundamental Ratings
ACAD
MIRM
OUTLOOK RATING
1..100
7310
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
1006
SMR RATING
1..100
2892
PRICE GROWTH RATING
1..100
4641
P/E GROWTH RATING
1..100
70100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIRM's Valuation (55) in the null industry is in the same range as ACAD (66) in the Biotechnology industry. This means that MIRM’s stock grew similarly to ACAD’s over the last 12 months.

MIRM's Profit vs Risk Rating (6) in the null industry is significantly better than the same rating for ACAD (100) in the Biotechnology industry. This means that MIRM’s stock grew significantly faster than ACAD’s over the last 12 months.

ACAD's SMR Rating (28) in the Biotechnology industry is somewhat better than the same rating for MIRM (92) in the null industry. This means that ACAD’s stock grew somewhat faster than MIRM’s over the last 12 months.

MIRM's Price Growth Rating (41) in the null industry is in the same range as ACAD (46) in the Biotechnology industry. This means that MIRM’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's P/E Growth Rating (70) in the Biotechnology industry is in the same range as MIRM (100) in the null industry. This means that ACAD’s stock grew similarly to MIRM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADMIRM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 8 days ago
71%
Bearish Trend 8 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
56%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signal:
Gain/Loss:
MIRM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WBELX11.550.13
+1.14%
William Blair Emerging Mkts Ldrs I
SMEFX19.900.21
+1.07%
Invesco Small Cap Equity R6
EKSCX6.56N/A
N/A
Allspring Diversified Income Bldr C
PSCJX25.21N/A
N/A
PGIM Jennison Small Company R4
TCIWX27.79N/A
N/A
Nuveen International Eq Idx W

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with STTK. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+1.80%
STTK - ACAD
39%
Loosely correlated
+5.47%
RXRX - ACAD
38%
Loosely correlated
+0.92%
AURA - ACAD
38%
Loosely correlated
+4.50%
MIRM - ACAD
37%
Loosely correlated
+2.02%
VCYT - ACAD
36%
Loosely correlated
-3.30%
More

MIRM and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with XERS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIRM
1D Price
Change %
MIRM100%
+2.02%
XERS - MIRM
53%
Loosely correlated
+1.27%
TARS - MIRM
42%
Loosely correlated
+2.16%
DNLI - MIRM
42%
Loosely correlated
+1.49%
IRON - MIRM
42%
Loosely correlated
+1.31%
RVMD - MIRM
41%
Loosely correlated
+1.65%
More